Viking Therapeutics: High-Stakes GLP-1 Play | Business and Finance News

Viking Therapeutics is betting big on its GLP-1 drug VK2735, racing through late-stage trials with a potential approval by mid to late 2028—if results are strong, it could rival Zepbound and generate billions. Their oral version, plagued by side effects, could unlock a massive new patient base if they solve that hurdle. Meanwhile, VK3019 offers another shot at obesity treatment. Valued at $4.4B despite being in trials, the company’s future hinges on trial success and market dynamics—high reward, high risk. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/883df5f94b1baf43